Has Vijay Yanamadala, MD received payments from drug or device companies?

Yes. Drug and device makers reported $85,031 in general payments to Vijay Yanamadala, MD across 117 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Vijay Yanamadala, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Vijay Yanamadala, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Vijay Yanamadala, MD

Neurological Surgery · Seattle, WANPI 1184986978

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (35.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Medtronic at 51.1% of the total. Reporting peaked in 2019 at $32,179 and has fallen 57.5% since, to $13,668 in 2025. Among neurological surgery clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$85,031in general payments, 2019–2025

Across 117 payments — averaging $726.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$43K
Hyhte Holdings Inc.$30K
Medical Device Business Services, Inc.$6K
Globus Medical$2K
Medicrea USA, Corp.$1K
Hikma Pharmaceuticals USA$421
plus $1K from 7 others

$1,275in research payments, 2019–2025

Across 1 payment — averaging $1275.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$1K

What the payments were for

Royalty or licence$30,18135%
Consulting fees$12,87615%
Speaking & faculty fees$28,94234%
Travel & lodging$8,10810%
Food & beverage$4,5315%
Education$3920%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	60	$43,479
Hyhte Holdings Inc.	3	$30,181
Medical Device Business Services, Inc.	11	$6,250
Globus Medical(2 entities)	10	$2,140
Medicrea USA, Corp.	7	$1,137
Hikma Pharmaceuticals USA	1	$421
Stryker	3	$421
Johnson & Johnson	11	$380
Corelink, LLC	1	$183
Boston Scientific	4	$168
Si-bone, Inc.	2	$163
Orthofix Medical, Inc.	3	$89
DJO, LLC	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,031 in reported general payments places this provider in the 95th percentile of 175 neurological surgery providers in Washington.

See all neurological surgery providers in Washington →

Medicare billing

Part B allowed, 2024

$133,064

Medicare patients

127

Services billed

400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	29	$282
Cyclobenzaprine Hcl	15	$238
Meloxicam	14	$41

Paid to pharmacies, not to this prescriber.

Other neurological surgery in Seattle

Rod OskouianSeattle$2.4M
Christoph HofstetterSeattle$768K
Stephen MonteithSeattle$151K
Jean-Christophe LevequeSeattle$120K
Hoan Vu TranSeattle$78K
Martin RutkowskiSeattle$62K
Bailey ZampellaSeattle$38K
Melanie WalkerSeattle$38K
Elias EliasSeattle$35K
Ryder GwinnSeattle$35K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →